Matches in SemOpenAlex for { <https://semopenalex.org/work/W2041617281> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2041617281 endingPage "945" @default.
- W2041617281 startingPage "944" @default.
- W2041617281 abstract "The 24-week, double-blind period of the ALLEGRO phase 2a trial (NCT02974868) evaluated the safety and efficacy of ritlecitinib (Jak3/tyrosine kinase expressed in the hepatocellular carcinoma inhibitor) and brepocitinib (tyrosine kinase 2/Jak1 inhibitor) in patients with alopecia areata; patients could subsequently continue treatment in a 24-week single-blind extension, followed by a crossover open-label extension, described in this article. Patients who did not achieve ≥30% improvement from baseline in Severity of Alopecia Tool score at the end of the single-blind extension entered a 24-week crossover open-label extension: the ritlecitinib group switched to brepocitinib, and the brepocitinib group switched to ritlecitinib. Eighteen patients switched to brepocitinib, and five switched to ritlecitinib. Six treatment-emergent adverse events were reported by five patients; no new safety risks were observed after crossover. An exploratory efficacy evaluation showed that none of the five patients receiving ritlecitinib in the crossover open-label extension achieved ≥30% improvement from baseline in Severity of Alopecia Tool score or improvement in eyebrow/eyelash assessments. Four of 16 patients receiving brepocitinib achieved ≥30% improvement from baseline in Severity of Alopecia Tool score or better; 4 of 15 and 5 of 12 showed improvement in eyebrow and eyelash assessments, respectively. Although the small number of patients precludes firm conclusions regarding efficacy, the data suggest that some patients with alopecia areata and inadequate response to ritlecitinib after ≥24 weeks show benefit after switching to brepocitinib." @default.
- W2041617281 created "2016-06-24" @default.
- W2041617281 creator A5018604493 @default.
- W2041617281 creator A5026359029 @default.
- W2041617281 creator A5044498054 @default.
- W2041617281 creator A5050799298 @default.
- W2041617281 creator A5057541132 @default.
- W2041617281 creator A5087337770 @default.
- W2041617281 creator A5088809131 @default.
- W2041617281 creator A5091814662 @default.
- W2041617281 date "2000-08-01" @default.
- W2041617281 modified "2023-09-27" @default.
- W2041617281 title "Inhibitory effect of cathepsin B inhibitor CA 074 on mouse anti-rat mixed lymphocyte reaction: novel immunosuppressive strategy for indirect xenoantigen recognition" @default.
- W2041617281 cites W2019091848 @default.
- W2041617281 cites W2022117658 @default.
- W2041617281 cites W2083575290 @default.
- W2041617281 cites W2095290410 @default.
- W2041617281 doi "https://doi.org/10.1016/s0041-1345(00)01051-4" @default.
- W2041617281 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10936287" @default.
- W2041617281 hasPublicationYear "2000" @default.
- W2041617281 type Work @default.
- W2041617281 sameAs 2041617281 @default.
- W2041617281 citedByCount "1" @default.
- W2041617281 crossrefType "journal-article" @default.
- W2041617281 hasAuthorship W2041617281A5018604493 @default.
- W2041617281 hasAuthorship W2041617281A5026359029 @default.
- W2041617281 hasAuthorship W2041617281A5044498054 @default.
- W2041617281 hasAuthorship W2041617281A5050799298 @default.
- W2041617281 hasAuthorship W2041617281A5057541132 @default.
- W2041617281 hasAuthorship W2041617281A5087337770 @default.
- W2041617281 hasAuthorship W2041617281A5088809131 @default.
- W2041617281 hasAuthorship W2041617281A5091814662 @default.
- W2041617281 hasConcept C126322002 @default.
- W2041617281 hasConcept C142724271 @default.
- W2041617281 hasConcept C16005928 @default.
- W2041617281 hasConcept C197934379 @default.
- W2041617281 hasConcept C204787440 @default.
- W2041617281 hasConcept C27081682 @default.
- W2041617281 hasConcept C2777524370 @default.
- W2041617281 hasConcept C2779884382 @default.
- W2041617281 hasConcept C54355233 @default.
- W2041617281 hasConcept C71924100 @default.
- W2041617281 hasConcept C86803240 @default.
- W2041617281 hasConcept C87813604 @default.
- W2041617281 hasConcept C90924648 @default.
- W2041617281 hasConceptScore W2041617281C126322002 @default.
- W2041617281 hasConceptScore W2041617281C142724271 @default.
- W2041617281 hasConceptScore W2041617281C16005928 @default.
- W2041617281 hasConceptScore W2041617281C197934379 @default.
- W2041617281 hasConceptScore W2041617281C204787440 @default.
- W2041617281 hasConceptScore W2041617281C27081682 @default.
- W2041617281 hasConceptScore W2041617281C2777524370 @default.
- W2041617281 hasConceptScore W2041617281C2779884382 @default.
- W2041617281 hasConceptScore W2041617281C54355233 @default.
- W2041617281 hasConceptScore W2041617281C71924100 @default.
- W2041617281 hasConceptScore W2041617281C86803240 @default.
- W2041617281 hasConceptScore W2041617281C87813604 @default.
- W2041617281 hasConceptScore W2041617281C90924648 @default.
- W2041617281 hasIssue "5" @default.
- W2041617281 hasLocation W20416172811 @default.
- W2041617281 hasLocation W20416172812 @default.
- W2041617281 hasOpenAccess W2041617281 @default.
- W2041617281 hasPrimaryLocation W20416172811 @default.
- W2041617281 hasRelatedWork W1972161773 @default.
- W2041617281 hasRelatedWork W2077633531 @default.
- W2041617281 hasRelatedWork W2117348672 @default.
- W2041617281 hasRelatedWork W2593279590 @default.
- W2041617281 hasRelatedWork W3049657126 @default.
- W2041617281 hasRelatedWork W3108514725 @default.
- W2041617281 hasRelatedWork W3210636663 @default.
- W2041617281 hasRelatedWork W4285153522 @default.
- W2041617281 hasRelatedWork W4292363424 @default.
- W2041617281 hasRelatedWork W4295254635 @default.
- W2041617281 hasVolume "32" @default.
- W2041617281 isParatext "false" @default.
- W2041617281 isRetracted "false" @default.
- W2041617281 magId "2041617281" @default.
- W2041617281 workType "article" @default.